CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis

Finn Sellebjerg*, C. Ross, N. Koch-Henriksen, P. Soelberg Sørensen, J. L. Frederiksen, K. Bendtzen, T. L. Sørensen

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review


    Biomarkers that allow the identification of patients with multiple sclerosis (MS) with an insufficient response to immunomodulatory treatment would be desirable, as currently available treatments are only incompletely efficacious. Previous studies have shown that the expression of CD25, CD26 and CCR5 on T cells is altered in patients with active MS. We studied the expression of these molecules by flow cytometry in patients followed for six months during immunomodulatory treatment. In interferon (IFN)-β-treated patients, we found that the hazard ratio for developing an attack was 2.8 in patients with CD26+CD4+ T cell counts above median, and this risk was independent of the risk conferred by neutralizing anti-IFN-β antibodies. CD26+CD+ T cell counts may identify patients with MS at increased risk of attack during treatment with IFN-β.

    Sider (fra-til)641-645
    Antal sider5
    TidsskriftMultiple Sclerosis
    Udgave nummer6
    StatusUdgivet - 1 dec. 2005


    Udforsk hvilke forskningsemner 'CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis' indeholder.